Zhongbao Zhou1,2, Shikai Zhao3, Youyi Lu2, Jitao Wu2, Yongwei Li2, Zhenli Gao2, Diandong Yang4, Yuanshan Cui5. 1. Binzhou Medical University, Yantai, Shandong, China. 2. Department of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, No. 20 East Yuhuangding Road, Yantai, 264000, Shandong, China. 3. Department of Andrology, The Liaocheng People's Hospital, Liaocheng, Shandong, China. 4. Department of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, No. 20 East Yuhuangding Road, Yantai, 264000, Shandong, China. 3098516949@qq.com. 5. Department of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, No. 20 East Yuhuangding Road, Yantai, 264000, Shandong, China. m15275525316@163.com.
Abstract
PURPOSE: We performed a meta-analysis to confirm the efficacy and safety of continuous saline bladder irrigation compared with intravesical chemotherapy after transurethral resection for the treatment of non-muscle invasive bladder cancer. METHODS: Randomized controlled trials of continuous saline bladder irrigation compared with intravesical chemotherapy were searched using MEDLINE, EMBASE, and the Cochrane Controlled Trials Register. The data were evaluated and statistically analyzed using RevMan version 5.3.0. RESULTS: Four studies including 861 participants which compared continuous saline bladder irrigation with intravesical chemotherapy were considered. One-year recurrence-free survival [odds ratio (OR) = 0.76, 95% CI = 0.55-1.05, p = 0.09]; 2-year recurrence-free survival (OR = 0.94, 95% CI = 0.71-1.25, p = 0.68); the median period to first recurrence (OR = - 1.01, 95% CI = - 2.96 to 0.94, p = 0.31); the number of tumor progression (OR = 0.80, 95% CI = 0.54-1.17, p = 0.25); and the number of recurrence during follow-up (OR = 1.12, 95% CI = 0.84-1.50, p = 0.43) suggested that two methods of postoperative perfusion had no significant differences. In terms of safety, including macrohematuria, frequency of urination and bladder irritation symptoms, continuous saline bladder irrigation showed better tolerance than intravesical chemotherapy. CONCLUSION: Continuous saline bladder irrigation seems to provide a better balance between prevention of recurrence and local toxicities than intravesical chemotherapy after transurethral resection of bladder tumors.
PURPOSE: We performed a meta-analysis to confirm the efficacy and safety of continuous saline bladder irrigation compared with intravesical chemotherapy after transurethral resection for the treatment of non-muscle invasive bladder cancer. METHODS: Randomized controlled trials of continuous saline bladder irrigation compared with intravesical chemotherapy were searched using MEDLINE, EMBASE, and the Cochrane Controlled Trials Register. The data were evaluated and statistically analyzed using RevMan version 5.3.0. RESULTS: Four studies including 861 participants which compared continuous saline bladder irrigation with intravesical chemotherapy were considered. One-year recurrence-free survival [odds ratio (OR) = 0.76, 95% CI = 0.55-1.05, p = 0.09]; 2-year recurrence-free survival (OR = 0.94, 95% CI = 0.71-1.25, p = 0.68); the median period to first recurrence (OR = - 1.01, 95% CI = - 2.96 to 0.94, p = 0.31); the number of tumor progression (OR = 0.80, 95% CI = 0.54-1.17, p = 0.25); and the number of recurrence during follow-up (OR = 1.12, 95% CI = 0.84-1.50, p = 0.43) suggested that two methods of postoperative perfusion had no significant differences. In terms of safety, including macrohematuria, frequency of urination and bladder irritation symptoms, continuous saline bladder irrigation showed better tolerance than intravesical chemotherapy. CONCLUSION: Continuous saline bladder irrigation seems to provide a better balance between prevention of recurrence and local toxicities than intravesical chemotherapy after transurethral resection of bladder tumors.
Authors: Maurizio Brausi; J Alfred Witjes; Donald Lamm; Raj Persad; Joan Palou; Marc Colombel; Roger Buckley; Mark Soloway; Hideyuki Akaza; Andreas Böhle Journal: J Urol Date: 2011-10-19 Impact factor: 7.450
Authors: Richard J Sylvester; Adrian P M van der Meijden; Willem Oosterlinck; J Alfred Witjes; Christian Bouffioux; Louis Denis; Donald W W Newling; Karlheinz Kurth Journal: Eur Urol Date: 2006-01-17 Impact factor: 20.096
Authors: Ashish M Kamat; Paul K Hegarty; Jason R Gee; Peter E Clark; Robert S Svatek; Nicholas Hegarty; Shahrokh F Shariat; Evanguelos Xylinas; Bernd J Schmitz-Dräger; Yair Lotan; Lawrence C Jenkins; Michael Droller; Bas W van Rhijn; Pierre I Karakiewicz Journal: Eur Urol Date: 2012-10-04 Impact factor: 20.096
Authors: Alan L Myers; Yan-Ping Zhang; Jitesh D Kawedia; Ximin Zhou; Stacey M Sobocinski; Michael J Metcalfe; Mark A Kramer; Colin P N Dinney; Ashish M Kamat Journal: Drugs R D Date: 2017-06
Authors: Jeremy Yuen-Chun Teoh; Ashish M Kamat; Peter C Black; Petros Grivas; Shahrokh F Shariat; Marek Babjuk Journal: Nat Rev Urol Date: 2022-03-31 Impact factor: 16.430
Authors: Sławomir Poletajew; Wojciech Krajewski; Paweł Stelmach; Jan Adamowicz; Łukasz Nowak; Marco Moschini; Piotr Zapała; Tomasz Drewa; Andrzej Paradysz; Piotr Radziszewski; Romuald Zdrojowy; Piotr Kryst Journal: Wideochir Inne Tech Maloinwazyjne Date: 2020-05-15 Impact factor: 1.195
Authors: Diego M Carrion; Juan Gómez Rivas; Cristina Ballesteros Ruiz; Mario Alvarez-Maestro; Alfredo Aguilera Bazán; Luis Martínez-Piñeiro Journal: Int J Surg Protoc Date: 2020-10-17